



September 25, 2013

AnGes MG, Inc.

**New Medical-use Patent for HGF Gene Therapy Granted in Japan  
- Combination Therapy with PGIS Gene Enhances Angiogenic Effect -**

AnGes MG, Inc. (AnGes) announced today that a medical-use patent has been granted in Japan for hepatocyte growth factor (HGF) gene combination therapy with enhanced angiogenic effect, and today the Patent Gazette (No. 5300157) was issued.

This grant covers combination gene therapy of HGF and prostacyclin synthase (PGIS). HGF gene therapy is expected to become an effective treatment against ischemic diseases, such as critical limb ischemia (peripheral arterial disease) and cardiac infarction. Combination gene therapy enhances the angiogenic action of HGF.

PGIS produces prostacyclin related to a vasodilating action and inhibition of platelet aggregation. In a pharmacological study using an arteriosclerosis obliterans (ASO) mouse model, PGIS gene therapy and HGF gene therapy showed a synergic effect in which the angiogenic action of HGF was enhanced by PGIS.

Regarding HGF gene therapy (Collategene<sup>®</sup>) for critical limb ischemia, AnGes is planning to resume development in Japan, as well as to start a global Phase III trial. This patent will strongly support the development of Collategene<sup>®</sup> as an option to enhance treatment efficacy after it receives approval as a treatment for critical limb ischemia.

AnGes has applied for other additional patents related to HGF gene therapy, and intends to expand future medical application.

This event has no effect on business performance for the fiscal year 2013.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a>
---